Fibrosis heterogeneity in nonalcoholic steatohepatitis and hepatitis C virus needle core biopsy specimens.

We examined 46 nonalcoholic steatohepatitis (NASH) and 52 hepatitis C virus (HCV) biopsy specimens to determine the magnitude of fibrosis heterogeneity and minimum length for accurate fibrosis staging. Three fibrosis scores were recorded: lowest regional, highest regional, and most common overall. Mean specimen lengths were 1.6 and 1.8 cm in NASH and HCV, respectively (P = .283). Mean (highest minus lowest) fibrosis heterogeneity scores (highest regional fibrosis - lowest regional fibrosis) were 3.7 and 2.0 in NASH and HCV, respectively (P < .001). Of 36 NASH specimens longer than 1.0 cm, 31 (86%) had the highest regional fibrosis in the deepest sampled parenchyma. Shorter specimens were associated significantly with greater fibrosis heterogeneity in NASH (coefficient, -1.3; P < .001) but not in HCV (P = .901). NASH specimens longer than 1.6 cm had significantly lower mean heterogeneity scores than specimens 1.6 cm or shorter (1.2 vs 3.4; P = .012). In NASH, fibrosis heterogeneity can be substantial and is greater than in HCV, and parenchymal injury, fibrosis, and healing might vary in different regions of the liver. The fibrosis stage in patients with NASH might not be assessed accurately in short specimens. Individual needle cores should be longer than 1.6 cm in NASH for accurate fibrosis staging.

[1]  S. Shalhub,et al.  The Importance of Routine Liver Biopsy in Diagnosing Nonalcoholic Steatohepatitis in Bariatric Patients , 2004, Obesity surgery.

[2]  K. Ishak,et al.  Histological grading and staging of chronic hepatitis. , 1995 .

[3]  P. Schlichting,et al.  Reproducibility of liver biopsy diagnosis in relation to the size of the specimen. , 1980, Scandinavian journal of gastroenterology.

[4]  J. Dixon,et al.  Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. , 2001, Gastroenterology.

[5]  D. Pessayre,et al.  Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes. , 1998, Gastroenterology.

[6]  I. Wanless,et al.  The pathogenesis of nonalcoholic steatohepatitis and other fatty liver diseases: a four-step model including the role of lipid release and hepatic venular obstruction in the progression to cirrhosis. , 2004, Seminars in liver disease.

[7]  Z. Younossi,et al.  Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. , 1999, Gastroenterology.

[8]  P. Hayashi,et al.  The natural history of nonalcoholic fatty liver disease: a clinical histopathological study , 2003, American Journal of Gastroenterology.

[9]  G. Del Gaudio,et al.  Liver Damage in Obese Patients , 2002, Obesity surgery.

[10]  P. Kar,et al.  Non-alcoholic steatohepatitis. , 2005, The Journal of the Association of Physicians of India.

[11]  J. Kalbfleisch,et al.  A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C , 2003, Hepatology.

[12]  V. Paradis,et al.  Sampling variability of liver fibrosis in chronic hepatitis C , 2003, Hepatology.

[13]  R. Hanson,et al.  The natural history of nonalcoholic steatohepatitis: A follow‐up study of forty‐two patients for up to 21 years , 1990, Hepatology.

[14]  E. Fábrega,et al.  Liver Transplantation in a Case of Steatohepatitis and Subacute Hepatic Failure after Biliopancreatic Diversion for Morbid Obesity , 2001, Obesity surgery.

[15]  G. Leandro,et al.  Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. , 2003, Journal of hepatology.

[16]  E. Brunt,et al.  Pathology of steatohepatitis. , 2002, Best practice & research. Clinical gastroenterology.

[17]  B. Bacon,et al.  Hepatic iron and nonalcoholic fatty liver disease , 1999, Hepatology.

[18]  Enrico Rossi,et al.  Validation of the FibroTest biochemical markers score in assessing liver fibrosis in hepatitis C patients. , 2003, Clinical chemistry.

[19]  A. Duchini,et al.  ROUX-EN-Y GASTRIC BYPASS FOR RECURRENT NONALCOHOLIC STEATOHEPATITIS IN LIVER TRANSPLANT RECIPIENTS WITH MORBID OBESITY , 2001, Transplantation.

[20]  E. Brunt.  Nonalcoholic Steatohepatitis: Definition and Pathology , 2001, Seminars in liver disease.

[21]  Randall G. Lee,et al.  Nonalcoholic steatohepatitis: a study of 49 patients. , 1989, Human pathology.

[22]  D. Pessayre,et al.  Acute and chronic hepatic steatosis lead to in vivo lipid peroxidation in mice. , 1996, Journal of hepatology.

[23]  J. Henriksen,et al.  Correlation Between Liver Morphology and Portal Pressure in Alcoholic Liver Disease , 1984, Hepatology.

[24]  Brian P. Mulhall,et al.  Nonalcoholic steatohepatitis , 2004, Current treatment options in gastroenterology.

[25]  D. Thabut,et al.  A prospective assessment of the inter-laboratory variability of biochemical markers of fibrosis (FibroTest) and activity (ActiTest) in patients with chronic liver disease , 2002, Comparative hepatology.

[26]  C. Gluud,et al.  Correlation between liver morphology and haemodynamics in alcoholic liver disease. , 2008, Liver.

[27]  B. Neuschwander‐Tetri,et al.  Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions , 1999, American Journal of Gastroenterology.

[28]  I. Grimm,et al.  Steatohepatitis and fatal hepatic failure after biliopancreatic diversion. , 1992, The American journal of gastroenterology.

[29]  F. Brancati,et al.  Nonalcoholic fatty liver disease. , 2002, Gastroenterology.

[30]  P. Christoffersen,et al.  Fatty liver persisting for up to 33 years. A follow-up of the inversen-roholm liver biopsy material. , 2009, Acta medica Scandinavica.

[31]  A. Baltasar,et al.  Clinical Hepatic Impairment after the Duodenal Switch , 2004, Obesity surgery.

[32]  P. Schlichting,et al.  Liver biopsy in chronic aggressive hepatitis. Diagnostic reproducibility in relation to size of specimen. , 1983, Scandinavian journal of gastroenterology.

[33]  M. Sherman,et al.  Regression of human cirrhosis. Morphologic features and the genesis of incomplete septal cirrhosis. , 2000, Archives of pathology & laboratory medicine.

[34]  T. Takahashi.  Lobular structure of the human liver from the viewpoint of hepatic vascular architecture. , 1970, The Tohoku journal of experimental medicine.

[35]  J. Crespo,et al.  Are there Predictive Factors of Severe Liver Fibrosis in Morbidly Obese Patients with Non-alcoholic Steatohepatitis? , 2001, Obesity surgery.

[36]  K. Kaneda,et al.  Liver microvascular architecture: an insight into the pathophysiology of portal hypertension. , 1999, Seminars in liver disease.

[37]  S. Caldwell,et al.  The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease. , 2004, Journal of hepatology.

[38]  M. Bondi,et al.  Hepatic steatosis in obese patients: clinical aspects and prognostic significance , 2004, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[39]  E. Mezey,et al.  Sampling variability on percutaneous liver biopsy. , 1979, Archives of internal medicine.

[40]  A. McCullough,et al.  Update on nonalcoholic fatty liver disease. , 2002, Journal of clinical gastroenterology.